AGTC Announces Significant Productivity and Quality Enhancement to Its Proprietary Manufacturing Process (Globe Newswire)

AGTC Announces Significant Productivity and Quality Enhancement to Its Proprietary Manufacturing Process

UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, provided an update on the continued productivity and quality improvements made in its proprietary manufacturing platform that is currently being used to create clinical trial material for the company’s planned pivotal clinical trials in X-linked retinitis pigmentosa (XLRP).

“Continuous improvements to our proprietary HSV-based manufacturing process have been a critical AGTC objective for more than a decade, and our efforts have resulted in AAV vector quality and yields that we believe exceed the performance and economics of other currently available approaches to produce AAV gene therapy products, particularly those using adherent cell platforms,” said Dr. Dave Knop, Ph.D., head of process development at AGTC.

Learn more about AGTC Announces Significant Productivity and Quality Enhancement to Its Proprietary Manufacturing Process.
X